Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
The British Journal of Surgery
|
January 26, 2019
Contralateral surgery in patients scheduled for total thyroidectomy with initial loss or absence of signal during neural monitoring
A Sitges-Serra, L Gallego-Otaegui, J Fontané, et al.
Clinical Neuropharmacology
|
January 1, 1994
Effects of moclobemide on depressive symptoms and cognitive performance in a geriatric population: a controlled comparative study versus imipramine
P Pancheri, R Delle Chiaie, M Donnini, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
June 22, 2019
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain
J L Poveda, J L Trillo, C Rubio-Terrés, et al.
Revista Espanola De Anestesiologia Y Reanimacion
|
November 1, 1990
[Degrees of acceptance of local regional anesthetic techniques among hospital physicians]
J M Campos Suárez, E Hansen Ferrer, L Trillo Urrutia, et al.
The British Journal of Surgery
|
January 24, 2013
Prospective study on loss of signal on the first side during neuromonitoring of the recurrent laryngeal nerve in total thyroidectomy
A Sitges-Serra, J Fontané, J P Dueñas, et al.
Frontiers in Public Health
|
July 28, 2025
Tight and early HbA<sub>1c</sub> control in patients with type 2 diabetes mellitus in Spain: quantifying the social value
María Merino, Paulina Maravilla-Herrera, Sara Artola, et al.
Advances in Therapy
|
January 27, 2026
Assessing the Value Contribution of Vyvgart<sup>®</sup> (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis
Elena Cortés-Vicente, Antonio Guerrero, Carmina Díaz, et al.
Advances in Therapy
|
March 12, 2026
Correction: Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis
Elena Cortés-Vicente, Antonio Guerrero, Carmina Díaz, et al.
BMC Public Health
|
November 25, 2010
Rationale and methods of the cardiometabolic Valencian study (Escarval-Risk) for validation of risk scales in Mediterranean patients with hypertension, diabetes or dyslipidemia
Vicente Gil-Guillen, Domingo Orozco-Beltran, Josep Redon, et al.
Plos One
|
March 15, 2014
Is the physician's behavior in dyslipidemia diagnosis in accordance with guidelines? Cross-sectional ESCARVAL study
Antonio Palazón-Bru, Vicente F Gil-Guillén, Domingo Orozco-Beltrán, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
The British Journal of Surgery
|
January 26, 2019
Contralateral surgery in patients scheduled for total thyroidectomy with initial loss or absence of signal during neural monitoring
A Sitges-Serra, L Gallego-Otaegui, J Fontané, et al.
Clinical Neuropharmacology
|
January 1, 1994
Effects of moclobemide on depressive symptoms and cognitive performance in a geriatric population: a controlled comparative study versus imipramine
P Pancheri, R Delle Chiaie, M Donnini, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
June 22, 2019
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain
J L Poveda, J L Trillo, C Rubio-Terrés, et al.
Revista Espanola De Anestesiologia Y Reanimacion
|
November 1, 1990
[Degrees of acceptance of local regional anesthetic techniques among hospital physicians]
J M Campos Suárez, E Hansen Ferrer, L Trillo Urrutia, et al.
The British Journal of Surgery
|
January 24, 2013
Prospective study on loss of signal on the first side during neuromonitoring of the recurrent laryngeal nerve in total thyroidectomy
A Sitges-Serra, J Fontané, J P Dueñas, et al.
Frontiers in Public Health
|
July 28, 2025
Tight and early HbA<sub>1c</sub> control in patients with type 2 diabetes mellitus in Spain: quantifying the social value
María Merino, Paulina Maravilla-Herrera, Sara Artola, et al.
Advances in Therapy
|
January 27, 2026
Assessing the Value Contribution of Vyvgart<sup>®</sup> (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis
Elena Cortés-Vicente, Antonio Guerrero, Carmina Díaz, et al.
Advances in Therapy
|
March 12, 2026
Correction: Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis
Elena Cortés-Vicente, Antonio Guerrero, Carmina Díaz, et al.
BMC Public Health
|
November 25, 2010
Rationale and methods of the cardiometabolic Valencian study (Escarval-Risk) for validation of risk scales in Mediterranean patients with hypertension, diabetes or dyslipidemia
Vicente Gil-Guillen, Domingo Orozco-Beltran, Josep Redon, et al.
Plos One
|
March 15, 2014
Is the physician's behavior in dyslipidemia diagnosis in accordance with guidelines? Cross-sectional ESCARVAL study
Antonio Palazón-Bru, Vicente F Gil-Guillén, Domingo Orozco-Beltrán, et al.
Page
of 5